YY/T 1216-2020 in English
VALIDAlpha-fetoprotein testing kit
- Issued on:2020-06-30
- Implemented on:2021-06-01
- File Format:PDF
- Delivery:Via email within 1~3 business days
$117.00
本标准规定了甲胎蛋白标记免疫测定试剂产品的分类、要求、检验方法、标示、标签、使用说明书、包装、运输和贮存等。本标准适用于以标记免疫测定为原理检测人血液基质或其它体液成分中的甲胎蛋白(AFP)定量测定试剂,包括以酶、化学发光、荧光物等方法标记捕获抗体,以微孔板、管、磁颗粒、微珠和塑料珠、微流控芯片、纳米材料等为载体包被抗体定量测定AFP的免疫测定试剂盒。本标准不适用于:胶体金标记AFP试纸条;用125I等放射性同位素标记的各类放射免疫。
Introduction
Analysis of the core content of the standard
This standard replaces YY/T 1216-2013, and mainly regulates the technical requirements, test methods and marking labels of alpha-fetoprotein detection kit. The key revisions include:
| Technical dimensions | Requirements of the 2013 version | Updates to the 2020 version |
|---|---|---|
| Linear range | Lower limit not specified | Added a new detection limit of 4.0IU/mL |
| Accuracy | Recovery 80%-120% | Tightened to 90%-110% |
| Precision | CV≤15% | Intra-batch CV≤8% Inter-batch CV≤10% |
Key technical requirements
1. Performance indicators
- Linear correlation coefficient: required to be ≥0.9900 (Clause 4.4)
- Detection limit: not higher than 16IU/mL (corresponding to 200ng/mL)
- Intra-batch precision: CV≤8.0% after 10 tests
2. Traceability of standards
The international unit (IU) is clearly adopted as the measurement basis, and manufacturers are required to provide the conversion relationship between IU/mL and ng/mL (Clause 5.5). Reference standards include:
- GB/T 21415-2008 Measurement of quantities in biological samples of in vitro diagnostic medical devices
- GB/T 29791.2-2013 In vitro diagnostic medical device instructions
Implementation recommendations
Precautions for manufacturers
Case: During method validation, a manufacturer found that the inter-batch CV was 9.5%, and the following improvements were required to meet the ≤10% requirement:
- Optimize the reconstitution process of calibrators
- Increase the frequency of quality control product testing
- Use more stable enzyme markers
Laboratory application guidelines
- After the implementation of the new standard, it is recommended to revalidate the analytical performance of the kit
- Focus on the detection accuracy in the low value range of 4.0-200IU/mL
- Regularly participate in external quality assessment and compare the results of different methodologies
Analysis of standard evolution
This revision mainly responds to the following technological developments:
- Increased demand for low-concentration AFP detection for early diagnosis of liver cancer
- Increased precision of new technologies such as chemiluminescence
- Updates to the requirements of in vitro diagnostic reagents in the international standard ISO 18113
After the implementation of the standard, it is expected that about 15% of ELISA kits that do not meet the accuracy requirements will be eliminated, and the market share of chemiluminescence alpha-fetoprotein detection kits will be increased to more than 80%.

Loading PDF document...
Error loading PDF. Please make sure the file is valid and try again.
We also recommend
-

YY/T 0688.2-2024 in English
Clinical laboratory testing and in vitro diagnostic systems - Performance evaluation of equipment for infectious pathogen susceptibility testing and antimicrobial susceptibility testing - Part 2: Performance evaluation of equipment for antimicrobial susce
2024-09-29 -

YY/T 0456.1-2014 in English
Reagents for hematology analyzer―Part 1:Rinse
2014-06-17 -

YY/T 0588-2017 in English
Flow cytometer
2017-12-05 -

YY/T 0996-2015 in English
Urine formed element analyzer(digital imaging automatic identification)
2015-03-02 -

YY/T 1303-2015 in English
Nucleic acid amplification reverse dot blot reagent(kit)
2015-03-02